UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ARRHYTHMIA RESEARCH TECHNOLOGY, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, Par Value $.01
--------------------------------------------------------------------------------
(Title of Class of Securities)
042698308
--------------------------------------------------------------------------------
(CUSIP Number)
Mr. Julius Tabin
Fitch, Even, Tabin & Flannery
120 South LaSalle Street, Suite 1600
Chicago, Illinois 60603
(312) 372-7842
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
November 14, 2002
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule
13G to report the acquisition which is the subject of this
Schedule 13D, and is filing this schedule because of Rule
13d-1(b)(3) or (4), check the following box [_].
Check the following box if a fee is being paid with the statement
[_]. (A fee is not required only if the reporting person: (1) has a
previous statement on file reporting beneficial ownership of more
than five percent of the class of securities described in Item 1;
and (2) has filed no amendment subsequent thereto reporting
beneficial ownership of five percent or less of such class.) (See
Rule 13d-7.)
NOTE: Six copies of this statement, including one original and
all exhibits, should be filed with the Commission. See Rule
13-d1(a) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in
a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18
of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).
CUSIP NO. 042698308 SCHEDULE 13D PAGE 2 OF 3 PAGES
--------------------------------------------------------------------------------
1. Name of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only).
Julius Tabin
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Source of Funds (See Instructions)
PF
--------------------------------------------------------------------------------
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
2(d) or 2(e) [_]
--------------------------------------------------------------------------------
6. Citizenship or Place of Organization
U.S.
--------------------------------------------------------------------------------
7. Sole Voting Power
138,824 Shares Common Stock, $.01 Par Value
Number of -------------------------------------------------------------
Shares 8. Shared Voting Power
Beneficially
by Owned by -------------------------------------------------------------
Each 9. Sole Dispositive Power
Reporting 138,824 Shares Common Stock, $.01 Par Value
Person With
-------------------------------------------------------------
10. Shared Dispositive Power
--------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
138,824 Shares Common Stock, $.01 Par Value
--------------------------------------------------------------------------------
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*
[_]
--------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
5.1%
--------------------------------------------------------------------------------
14. Type of Reporting Person (See Instructions)
IN
--------------------------------------------------------------------------------
*See Instructions before filling out.
CUSIP NO. 042698308 SCHEDULE 13D PAGE 3 OF 3 PAGES
--------------------------------------------------------------------------------
Item 1. Security and Issuer
This statement relates to the $.01 Par Value Common Stock ("Common Stock")
of Arrhythmia Research Technology, Inc. ("ART"), the principal executive offices
of which are located at 25 Sawyer Passway, Fitchburg, Massachusetts 01420
Item 2. Identity and Background
(a) Julius Tabin
(b) Mr. Tabin's business address is Fitch, Even, Tabin & Flannery, 120
South LaSalle Street, Suite 1600, Chicago, IL 60603
(c) Mr. Tabin's principal occupation is as a partner in the previous
listed law firm.
(d) Mr. Tabin has not been convicted in a criminal proceeding (excluding
traffic violations or similar misdemeanors) during the last five
years.
(e) Mr. Tabin has not been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction and as a result of any
such proceeding was or is subject to a judgment, decree, or final
order enjoining future violations of, or prohibiting or mandating
activities subject to, federal or state securities laws or finding any
violation with respect to such laws during the last five years.
(f) Mr. Tabin is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Consideration
The Common Stock of ART acquired by Mr. Tabin has been purchased for
an aggregate cash consideration of $158,236.14, utilizing personal funds.
Item 4. Purpose of Transaction
Mr. Tabin has purchased the Common Stock of ART for investment
purposes.
Item 5. Interest in Securities of the Issuer
(a) The aggregate number of shares of Common Stock of ART beneficially
owned by Mr. Tabin and the percentage which those shares are of the
outstanding Common Stock of ART are as follows:
Julius Tabin 138,824 shares 5.1%
(b) Mr. Tabin has the sole power to vote and the sole power to dispose
or direct the disposition of all of the shares of Common Stock
listed in subpart (a) of this Item.
(c) The following transactions in the Common Stock of ART were
completed to attain 5% ownership:
Amount of Price / Where and Amount of Price / Where and How
---------- ------- --------- --------- ------- -------------
Date Securities Share How Effected Date Securities Share Effected
---- ---------- ----- ------------ ---- ---------- ----- --------
11/06/87 15,000* Initial 10/08/98 3,200 $1.0625 Open Market
03/08/88 3:2 Rev Stk Split 10/13/98 8,000 $1.0625 Open Market
07/21/88 4,809* 10/15/98 200 $1.0625 Open Market
05/23/89 566* 10/23/98 1,700 $1.0625 Open Market
09/06/89 2:1 Rev Stk Split 10/27/98 6,700 $1.0625 Open Market
08/06/90 2:1 Rev Stk Split 10/28/98 200 $1.0625
03/01/95 8,103 $1.88 Open Market 04/23/99 8,333 $1.0000 Comp.for Dir.Svcs
08/27/97 20,400 $1.88 Open Market 05/10/00 4,103 $1.5000 Comp.for Dir.Svcs
09/02/97 6,500 $1.88 Open Market 01/10/02 8,000 $1.0625 Exercise Opts
09/03/97 3,100 $1.88 Open Market
* Reverse split adjusted quantity
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer
Mr. Tabin does not have any contracts, arrangements, understandings, or
relationships (legal or otherwise) with any persons with respect to any
securities of ART, including but not limited to transfer or voting of any
securities of ART, finders fees; joint ventures; loan or option arrangements;
puts or calls; guarantees of profits; divisions of profits or losses; or the
giving or withholding of proxies.
After reasonable inquiry and to the best knowledge and belief of each, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Dated: November 22, 2002 /s/ Julius Tabin
----------------
Julius Tabin